Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 141 to 150 of 2443 total matches.
A New Dihydroergotamine Nasal Spray (Trudhesa) for Migraine
The Medical Letter on Drugs and Therapeutics • Dec 27, 2021 (Issue 1640)
it is still mild to moderate in intensity
improves headache response and reduces the risk
of recurrence.1 ...
The FDA has approved Trudhesa (Impel Neuropharma),
a new dihydroergotamine nasal spray
product, for acute treatment of migraine with or
without aura in adults. Another dihydroergotamine
nasal spray (Migranal, and generics) has been
available for many years for the same indication.
Rasagiline (Azilect) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Dec 04, 2006 (Issue 1249)
),
1
which prolongs the effects of levodopa. Amantadine (Symmetrel, and others) has
some dopaminergic ...
Rasagiline (Azilect - Teva), a monoamine oxidase-type B (MAO-B) inhibitor, was recently approved by the FDA for once-daily oral treatment of Parkinson's disease (PD). It can be taken alone for treatment of early disease or with levodopa/carbidopa (Sinemet, and others) for advanced disease. Selegiline (Eldepryl, and others), the first MAO-B inhibitor marketed in the US, has been available since 1988; a new lower-dose disintegrating tablet (Zelapar) was recently approved.
Deucravacitinib (Sotyktu) for Plaque Psoriasis
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
as methotrexate, but its use
is generally restricted to 1-2 years because of a risk
of irreversible ...
The FDA has approved deucravacitinib (Sotyktu –
BMS), an oral tyrosine kinase 2 (TYK2) inhibitor, for
once-daily treatment of moderate to severe plaque
psoriasis in adults who are candidates for systemic
therapy or phototherapy. Deucravacitinib is the first
selective TYK2 inhibitor to be approved in the US for
any indication.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):29-31 doi:10.58347/tml.2023.1670b | Show Introduction Hide Introduction
Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
and as an adjunct to antidepressants for
treatment of major depressive disorder.1
Key Points: Brexpiprazole ...
The FDA has approved the oral second-generation
antipsychotic drug brexpiprazole (Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated
with dementia due to Alzheimer's disease (AD).
Brexpiprazole is the first drug to be approved in the US
for this indication. It is also approved for treatment of
schizophrenia and as an adjunct to antidepressants for
treatment of major depressive disorder.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):99-101 doi:10.58347/tml.2023.1679b | Show Introduction Hide Introduction
A New Ace Inhibitor and Two New Angiotensin Receptor Blockers For Hypertension
The Medical Letter on Drugs and Therapeutics • Nov 05, 1999 (Issue 1065)
Benazepril − Lotensin (Norvartis) 10-40 mg in 1 or 3 doses $27.60
Captopril − generic price 25-150 mg in 2 ...
Perindopril, the tenth angiotensin converting enzyme (ACE) inhibitor to be marketed in the USA, and telmisartan and eprosartan, the fifth and sixth angiotensin receptor blockers, have recently become available for treatment of hypertension.
Vonvendi - Recombinant von Willebrand Factor (online only)
The Medical Letter on Drugs and Therapeutics • May 22, 2017 (Issue 1521)
(Stimate, and others; 1-deamino-8-
D-arginine vasopressin, DDAVP) stimulates release
of VWF and factor ...
The FDA has approved intravenously administered
recombinant von Willebrand factor (Vonvendi - Shire)
for adults with von Willebrand disease (VWD) who
require on-demand treatment and control of bleeding
episodes. It is the first recombinant von Willebrand
factor (VWF) product to become available in the US.
Dapagliflozin/Saxagliptin (Qtern) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018 (Issue 1543)
with extended-release metformin
(Xigduo XR; Kombiglyze XR).1 Three SGLT2/DPP-4
inhibitor combinations are now ...
The FDA has approved Qtern (AstraZeneca), a
fixed-dose combination of the sodium-glucose
co-transporter 2 (SGLT2) inhibitor dapagliflozin
(Farxiga) and the dipeptidyl peptidase-4 (DPP-4)
inhibitor saxagliptin (Onglyza), for oral treatment
of adults with type 2 diabetes. Dapagliflozin and
saxagliptin have each been available for years alone
and in combination with extended-release metformin
(Xigduo XR; Kombiglyze XR). Three SGLT2/DPP-4
inhibitor combinations are now available in the US
(see Table 2).
ZTlido - A New Lidocaine Patch for Postherpetic Neuralgia
The Medical Letter on Drugs and Therapeutics • Mar 25, 2019 (Issue 1568)
ZTlido — A New Lidocaine Patch
for Postherpetic Neuralgia
A lidocaine 1.8% patch (ZTlido – Scilex ...
A lidocaine 1.8% patch (ZTlido – Scilex) has been
approved by the FDA for treatment of pain associated
with postherpetic neuralgia (PHN). A lidocaine 5%
patch (Lidoderm, and generics) was approved earlier
for the same indication and has been used off-label
for treatment of other types of localized pain. Both
of these patches are available only by prescription.
Lidocaine 4% patches (Aspercreme, IcyHot, and others)
are available over the counter for back, neck, shoulder,
and joint pain.
Peanut Allergen Powder (Palforzia)
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020 (Issue 1593)
group than in the placebo group (see Table 1).4
ADVERSE EFFECTS — The most common adverse
effects ...
The FDA has approved peanut allergen powder-dnfp
(Palforzia – Aimmune) for use as oral immunotherapy
to mitigate allergic reactions, including anaphylaxis,
caused by accidental peanut exposure in patients with
a confirmed peanut allergy. It is the first drug to be
approved in the US for this indication; Viaskin Peanut,
an immunotherapy patch, is under FDA review for the
same indication.
Relyvrio for ALS
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
earlier.1,2
CLINICAL STUDIES ― FDA approval of Relyvrio
was based on the results of a double-blind phase ...
The FDA has approved Relyvrio (Amylyx), a fixed-dose
combination of sodium phenylbutyrate and
taurursodiol, for treatment of amyotrophic lateral
sclerosis (ALS). Sodium phenylbutyrate (Buphenyl,
and others) has been available by prescription
for years for treatment of urea cycle disorders.
Taurursodiol (tauroursodeoxycholic acid), a derivative
of ursodiol, is an over-the-counter bile acid
supplement claimed to have neuroprotective
benefits. Relyvrio is the third drug to be approved
in the US for treatment of ALS; riluzole (Rilutek, and
others) and edaravone (Radicava, Radicava...